Liraglutide Effect in Atrial Fibrillation

Summary

The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.

Timeline

Start

2019-03-18

Primary completion

2026-12-31

Completion

2026-12-31

Publications

• Goldberger JJ, Mitrani RD, Fishman J, Zaatari G, Lowery M, Baez-Garcia C, Aguilar V, Blandon C, Hurwitz BE, Velasquez AH, Lambrakos LK, Dey D, Zarnegarnia Y, Iacobellis G. The Liraglutide Effects in Atrial Fibrillation (LEAF) Study. JACC Clin Electrophysiol. 2026 Mar 30:S2405-500X(26)00270-7. doi: 10.1016/j.jacep.2026.03.026. Online ahead of print.

Drugs

Indications